Lehi, Utah — May 13, 2025 — Lumea, a leader in digital pathology and workflow innovation, is pleased to announce the upcoming transition of the Chief Executive Officer role, which will transition from Jim Pack to James Thackeray next month.
Jim Pack, who joined Lumea following a distinguished career scaling healthcare software companies, served as a transitional CEO and will continue to lend his expertise in a new capacity—as a strategic advisor and active member of the Board of Directors. During his tenure as a succession-focused CEO, Lumea experienced remarkable momentum, expanding its international reach, strengthening its product and research pipeline, positioning the company for long-term success, and preparing the next generation of leadership.
James Thackeray has served as Lumea’s Chief Commercial Officer for more than eight years, guiding the company from its early commercial stages to becoming an industry leader. His deep understanding of the market, customers, and company mission has been instrumental in driving Lumea’s impressive growth and innovation trajectory.
As Lumea continues to scale to meet the demands of a rapidly expanding market, this leadership transition reflects the company’s commitment to long-term growth and success. James’ leadership, strategic vision, and relentless focus on execution make him ideally suited to guide Lumea into its next chapter.
“I want to express deep gratitude to Jim Pack for leading Lumea through a transformative chapter in our company’s history. He personifies a servant-leader, quietly reigniting this company’s spirit, strengthening the culture of our teams, and achieving great results. Jim will continue to be involved in mentoring and guiding the company as a member of Lumea’s Board of Directors,” said Matt Leavitt, MD, Lumea Founder and Board Chair. “We eagerly anticipate the great leadership of James Thackeray, who will carry Lumea’s torch of innovation forward beginning in early June.”
This leadership evolution marks a continuation of Lumea’s mission to deliver efficient, precise, and accessible pathology through workflow-driven innovation.
About Lumea
Lumea, a forefront innovator in digital pathology, places patients at the core of its approach. Their best-in-class tissue-handling technology and integrated workflow AI ensure standardization and optimal tissue integrity throughout the entire pathology ecosystem, enhancing overall efficiency and quality. This distinctive strategy improves tissue yield and quality, which can lead to higher cancer detection rates and results in a superior return on investment in cost and time-sensitive environments, ultimately setting a higher standard for patient care and cancer diagnostics. Learn more at www.lumeadigital.com
